Most cell types acquire cholesterol by endocytosis of circulating LDL, but little is known about the mechanisms of intraendosomal cholesterol transport -and about the primary cause of its aberrant accumulation in the cholesterol storage disorder Niemann-Pick type C (NPC). Here, we report that lysobisphosphatidic acid (LBPA) -an unconventional phospholipid that is only detected in late endosomesregulates endosomal cholesterol levels under the control of Alix/AlP1, which is an LBPA interacting protein involved in sorting into multivesicular endosomes. We find that Alix down-expression decreases both LBPA levels and the lumenal vesicle content of late endosomes. Cellular cholesterol levels are also decreased, presumably because the storage capacity of endosomes is affected and thus cholesterol clearance accelerated. Both lumenal membranes and cholesterol can be restored in Alix knockdown cells by exogenously added LBPA. Conversely, we also find that LBPA becomes limiting upon pathological cholesterol accumulation in NPC cells, since the addition of exogenous LBPA, but not of LBPA isoforms or analogs, partially reverts the NPC phenotype. We conclude that LBPA controls the cholesterol capacity of endosomes.
Most cell types acquire cholesterol by endocytosis of circulating LDL, but little is known about the mechanisms of intraendosomal cholesterol transport -and about the primary cause of its aberrant accumulation in the cholesterol storage disorder Niemann-Pick type C (NPC). Here, we report that lysobisphosphatidic acid (LBPA) -an unconventional phospholipid that is only detected in late endosomesregulates endosomal cholesterol levels under the control of Alix/AlP1, which is an LBPA interacting protein involved in sorting into multivesicular endosomes. We find that Alix down-expression decreases both LBPA levels and the lumenal vesicle content of late endosomes. Cellular cholesterol levels are also decreased, presumably because the storage capacity of endosomes is affected and thus cholesterol clearance accelerated. Both lumenal membranes and cholesterol can be restored in Alix knockdown cells by exogenously added LBPA. Conversely, we also find that LBPA becomes limiting upon pathological cholesterol accumulation in NPC cells, since the addition of exogenous LBPA, but not of LBPA isoforms or analogs, partially reverts the NPC phenotype. We conclude that LBPA controls the cholesterol capacity of endosomes.
Endocytosed proteins and lipids destined for degradation, such as downregulated signaling receptors and LDL, are sequentially transported to early and late endosomes, and eventually to lysosomes. A hallmark of endosomes along this degradation pathway is their multivesicular appearance due to the accumulation of intralumenal vesicles. These incorporate downregulated receptors (1, 2) and cholesterol (3, 4) , and also contain large amounts of LBPA (or BMP, bis(monoacylglycero)phosphate), which is only detected in late endosomes (5) .
In addition to their presence in intralumenal vesicles, LBPA and cholesterol have been linked functionally. Both are affected by sterol carrier protein-2 expression (6). Moreover, LBPA plays a role in cholesterol transport (7) . Some relationship between cholesterol and LBPA has also been revealed in the cholesterol storage disorder Niemann-Pick type C caused by mutations in NPC1 or NPC2, whose precise functions are not known (8) (9) (10) . In tissues from NPC patients, cholesterol accumulation is paralleled by the accumulation of LBPA and other lipids, in particular sphingolipids (8, (10) (11) (12) . We previously found that LBPA functions may be controlled by Alix, which binds LBPA-containing bilayers (13) . Interestingly, Alix is involved in sorting into multivesicular endosomes (14, 15) . Moreover, both Alix and LBPA also play a role in intralumenal vesicle fission from and fusion with the endosome limiting membrane (13, 16, 17) .
Here, we report that Alix downexpression decreases both the lumenal membrane content of late endosomes and their LBPA level, while the cellular cholesterol level is reduced, presumably because the endosomal storage capacity is affected. Indeed, the addition of exogenous LBPA to Alix knockdown cells restores both the intralumenal membrane content of late endosomes and the cholesterol level. Conversely, we find that LBPA becomes limiting upon pathological cholesterol accumulation in NPC cells, since the addition of exogenous LBPA, but not of LBPA isoforms or analogs, reverts the NPC phenotype. We conclude that LBPA controls the cholesterol storage capacity of endosomes.
EXPERIMENTAL PROCEDURES
Cells and reagents -Baby Hamster kidney cells (BHK-21), HeLa cells and NPC skin fibroblasts were maintained as described previously (7), as was the production and purification of vesicular stomatitis virus (VSV Indiana serotype) (18) . We previously described the synthesis of enantiopure 2,2'-and 3,3'-dioleoyl LBPA (13, 19) , which can now be obtained from Echellon Biosciences Inc. (Salt Lake City, USA) and of (R,R)-and (S,S)-bisether analogues of LBPA (20) . Other lipids were purchased from Avanti Polar Lipids, Inc. (Alabama, USA). We also previously described the 6C4 monoclonal antibody against LBPA (5). The monoclonal antibodies against a cytoplasmic (P5D4) (21) TM RT (Invitrogen, Scotland, UK) using random hexamer. The transcribed DNA was subjected to TaqMan RT-PCR using two primers (forward primer: 5' GGT GCA GCT GAA GAA GAC CT 3'; reverse primer: 5' CAG GTT CTG CTC TGC AAT 3'). For TaqMan real-time PCR we used the ICycler.IQ TM (Bio-Rad laboratory, PA). Specific PCR bands were excised and purified. The DNA was cloned into a TOPO vector Invitrogen, (Scotland, UK) according to the manufacturer's instructions. TOP10 bacteria were then transformed and grown; DNA was isolated and then sequenced for analysis by Fasteris SA (Geneva, Switzerland). Microscopy -The analysis of cholesterol distribution after filipin staining by fluorescence microscopy was described, as was the analysis of LBPA (7) or other antigens (17) by immunofluorescence microscopy. To visualize the content of late endosomes by electron microscopy, HRP was endocytosed for 15min at 37°C and then chased for 30min in marker-free medium (18) . Cells were then fixed, HRP was revealed cytochemically with DAB as substrate, and processed for plastic embedding (23) . Micrographs were taken at random across the monolayer and then sets of micrographs were analysed in a blind fashion by an independent observer. Proteoliposomes containing VSV-G protein and LBPA -The major LBPA (>90%) isoform in BHK is 2,2'-dioleoyl LBPA (5, 19, 24) . This isoform was synthesized (19) and used to prepare liposomes by reverse phase evaporation with a phospholipid composition (DOPC:DOPE:LBPA; 60:20:20 mol) similar to that of late endosomes, where LBPA normally resides (5) . Since living cells do not take up liposomes efficiently, the Gglycoprotein of vesicular stomatitis virus (VSV-G) was incorporated into the liposomes, to increase cell surface binding and targeting to the endocytic pathway. Thus, liposome delivery was independent of the lipid composition. To prepare the G-protein, purified VSV (800µg) was sedimented for 2h at 4°C in a TLA100.3 centrifuge at 90Krpm. The supernatant was carefully discarded. The white pellet was resuspended in 0.6ml of 0.1% n-octylPOE in HBS (20mM Hepes, pH 7.4, 150mM NaCl), by 6-8 passages through a yellow tip until the solution became clear. Then, the tubes were gently mixed at room temperature on a rotary wheel (4 rpm) (in 0.6 ml) for 1h, to facilitate detergent extraction of the G protein. The mixture was then centrifuged at 4°C for 1h at 50Krpm (TLA 100.3) to separate soluble and non-soluble materials. The supernatants were collected; dialyzed 6X against 250ml HBS at 4°C, to remove the detergent, and used to prepare proteoliposomes or aliquoted, flash-frozen in liquid N2, and stored at -90°C. Lipsomes were prepared by reverse phase evaporation (13) (13) . When living cells (grown in 6cm diameter Petri dishes) were treated with liposomes, the growth medium was replaced by 3ml G-MEM containing 10mM Hepes pH 7.4 and 0.2% BSA, which was then complemented with 100µl of the desired liposome preparation (0.66mg total lipid). The same operation was then repeated every 2h, until the end of the incubation (after 8h). To quantify the incorporation of VSV-G and to determine its trans-bilayer orientation, proteoliposomes (prepared by reverse phase evaporation as above), were immunopurified using Dynabeads coated with antibodies against an exoplasmic (17.2.21.4) or cytoplasmic (P5D4) epitope of the G-protein (18) . Similarly, we analyzed the antigenicity of LBPA incorporated into liposomes by incubating 50µl of the liposome preparation with 15µl anti-LBPA antibody in 135µl HBS for 3hrs at 4°C. Then, the antibody bound to liposomes was separated from free antibody by floatation in a step sucrose gradient (17) . In each case, samples were analyzed by SDS gel electrophoresis under nonreducing conditions, followed by western blotting using a polyclonal antibody against VSV-G to detect the G-protein, or anti-mouse antibodies to detect the anti-LBPA antibody. To determine the pH-dependent fusion properties of liposomes, we used: 1) as acceptor: DOPC:DOPE:LBPA (60:20:20) liposomes containing the G-protein; 2) as donor containing R18; liposomes were passed through a PD-10 Sephadex G-25 column from Amersham Biosciences (Little Chalfont, United Kingdom) to remove the non encapsulated dye R18. Then, 100µl donor R18-liposomes were mixed at 4°C with 50µl of acceptor liposomes and 50µl HBS (neutral conditions) or 50µl Tris Maleic acid pH 5.6 in 150 mM NaCl (acidic conditions). The temperature was raised to 22°C and the emitted fluorescence (ex: 560; em: 585) was measured over 90min with a Photon Technology International fluorimeter (710 Photomultiplier system detection and LPS 220 lamp).
Other methods -SDS gel electrophoresis (25) and the quantification of LBPA by ELISA (5) and cholesterol (26) were described. Downregulation of Alix expresssion in BHK cells with siRNAs was as described in HeLa cells (13) except that cells were split (1/20) the day before the experiment and then again (biochemistry: 1/4; immunofluorescence:1/20) 48h after siRNA addition. Gene expression was quantified from HeLa cells submitted or not to Alix siRNAs. For each condition, RNA was purified from 2 independent 10cm dishes using the RNeasy minikit (Qiagen). RT PCR was performed using the Superscript II kit (Invitrogen), and oligodT primer (Promega). The following amplification was made on an icycler (Biorad) with the Qantitect SYBR Green PCR kit (Qiagen). The Quantitect Primers (Qiagen) for the following genes were used: SREBPF2, DHC7R, ACTB, HMGCR, SDHA, LDLR, PDCD6IP (Alix).
RESULTS AND DISCUSSION

Formation of intralumenal membranes.
To investigate LBPA functions in cholesterol storage and transport, we silenced Alix expression in baby hamster kidney (BHK) cells (Fig S1A) , because we had characterized LBPA in these cells. We had determined the atomic composition of the BHK major (>90%) LBPA isoform as 2,2'-dioleoylLBPA ( Fig S1B) . We had also characterized the subcellular distribution and late endosomal content of LBPA (15Mol% of total phospholipids) in BHK cells (5, 19, 24 ) (see Fig 1C) . Upon Alix knockdown (Fig 1C, inset) , the LBPA staining intensity was decreased (Fig 1A) , as observed by others (27) and us (13) in human cells, as was the LBPA content of late endosomal fractions ( Fig 1C) .
Since LBPA is a major phospholipid of late endosome lumenal membranes (5) and since it is decreased by Alix knockdown, we wondered whether the ultrastructure of late endosomes was affected in Alix knockdown cells. To this end, the lumen of late endosomes was labeled with endocytosed HRP pulsed for 15min and then chased for 30min at 37°C. Cells were then processed for HRP cytochemistry and electron microscopy, and micrographs taken at random were analyzed in a blind fashion. In control, mock-treated cells, HRP-labelled late endosomes contained numerous luminal inclusions and vesicles, exhibiting the characteristic multivesicular ultrastructure of this compartment in BHK cells (18) (Fig 1D) . By contrast, in Alix knockdown cells, HRP-positive endosomes appeared like empty vacuoles with few internal vesicles (Fig 1E) , consistent with observations that LBPA levels are then reduced (Fig 1A-C) . These data agree well with our previous findings that Alix knockdown in HeLa cells reduces LBPA levels and the number of multilamellar late endosomes that are typical for these cells (13) . Alix and cholesterol. We then investigated whether cholesterol was affected in Alix knockdown cells, since LBPA and cholesterol are linked functionally (6) (7) (8) 12 ) and since LBPA and cholesterol are both present in intralumenal endosomal vesicles, although perhaps in different subpopulations (3, 28) . Upon filipin staining of mock-treated control cells, cholesterol was mostly present at the plasma membrane by light microscopy, but also faintly detected in intracellular structures, presumably TGN and endosomes (Fig 1A) , as expected (8, 29) . Strikingly, the overall cholesterol staining intensity decreased in Alix knockdown cells concomitantly with decreased LBPA staining (Fig 1A) , and biochemical quantification showed that, much like LBPA, the total cellular cholesterol was then reduced by ≈ 30% (Fig 1B) .
We could rule out the possibility that decreased cholesterol levels were due to an inhibition of LDL endocytosis, since Alix knock down does not affect endocytosis, nor transport along the endocytic pathway towards late endosomes and lysosomes or lysosomal degradation (13, 16, 17, 27, 30) . Similarly, Alix knockdown did not seem to affect de novo cholesterol synthesis, since the expression of genes involved in cholesterol synthesis and accumulation was unchanged (Fig S2) . Alternatively, Alix downexpression, with a concomitant depletion of LBPA (Fig 1 A-C) and loss of luminal membranes (Fig 1E) , may affect the capacity of multivesicular endosomes to store or retain cholesterol. This may affect NPC1 functions in cholesterol transport, since NPC1 is normally present both in intraluminal vesicles and on the limiting membrane of multivesicular endosomes (31) . In turn, this may alter cellular cholesterol levels, since endosomal and cellular cholesterol levels are interdependent (29) . Upon release from endosomes, perhaps via NPC1 and NPC2, as well as ABCA1 (32) or other members of this protein superfamily (33) , cholesterol is rapidly transported to the cell surface (34-36) by vesicular and non-vesicular routes (29) . Efflux into the medium and capture by serum carriers, including HDL (37) can then occur. We could not measure cholesterol in the medium, because of the necessary presence of FCS in these RNAi experiments. However, we hypothesized that in the absence of Alix and LBPA, cholesterol may be inefficiently retained in endosomes, and thus cellular clearance may be accelerated.
Cholesterol accumulation. To test whether Alix and LBPA may play a role in cholesterol clearance from endosomes, we made use of U18666A, a drug that mimics the NPC phenotype by causing acute accumulation of LDL-derived cholesterol in the late endosomes of cells with a non-pathological genetic background (7, 38) (Fig 2A-B) . Interestingly, LBPA and cholesterol levels changed concomitantly in U18666A-treated cells. Like cholesterol, LBPA increased in U18666A-treated cells incubated in the presence of serum ( Fig  2B) . Conversely, cholesterol did not accumulate in U18666A-treated cells incubated in serumfree medium (Fig 2B) , as expected (38). LBPA similarly showed no increase in U18666A-treated cells incubated in serum-free medium (Fig 2B) , demonstrating that LBPA accumulation in U18666A-treated cells did not result from some effects of the drug on lipid neo-synthesis, and further confirm the notion that LBPA and cholesterol are intimately linked.
Cholesterol accumulated within intracellular vesicles in U18666A-treated cells, as predicted (38) (Fig 2A) , which correspond to LBPA-positive late endosomes (7) and not shown). In Alix knockdown cells, accumulation still occurred albeit with slower kinetics (Fig S3) , and eventually reached levels comparable to controls (Fig 2A t=0 ; after 16h U18666A treatment). We then monitored cholesterol clearance from these pre-loaded endosomes after drug washout. The intensity of the cholesterol staining rapidly (over 6h) decreased in Alix by on November 13, 2008 www.jbc.org Downloaded from knockdown cells, when compared to controls (Fig 2A) . This may suggest that U18666A was less efficiently retained within the endosomes of knockdown cells upon washout. Alternatively, it is possible that cholesterol was more efficiently cleared from endosomes after Alix knockdown, consistent with the notion that Alix and LBPA may be involved in endosomal cholesterol retention.
LBPA addition using liposomes. To further investigate the putative role of Alix and/or LBPA in cholesterol retention, we decided to re-complement Alix siRNA-treated cells with LBPA, using LBPA-containing liposomes. To this end, we synthesized enantiomerically pure RR 2,2'-dioleoyl LBPA (19) , the major (>90%) isoform in BHK cells (5, 24) (Fig S1B) . The synthetic lipid was then used to prepare liposomes with a phospholipid composition (DOPC:DOPE:LBPA; 60:20:20 mol) similar to that of late endosomes, where LBPA normally resides (5) . Since living cells do not take up liposomes efficiently the Gglycoprotein of vesicular stomatitis virus (VSV-G) was incorporated into the liposomes to increase cell surface binding and targeting to the endocytic pathway (17) . The proteoliposomes bound anti-LBPA antibodies, but not isotypic control antibodies (Fig S4A) , indicating that LBPA had retained its antigenic properties in the liposome bilayer, and was thus presumably present in the same biophysical state as in native membranes. The G-protein was predominantly incorporated in its correct orientation, since liposomes could be immuno-purified with antibodies against an exoplasmic, but not a cytoplasmic, G-protein epitope (Fig S4B) . Finally, these LBPA-and G-containing proteoliposomes were highly fusogenic at low pH, but not at neutral pH (Fig S4C) , much like VSV itself.
We then tested whether the liposomes containing exogenous LBPA were properly targeted to endosomes. Liposomes were labeled with self-quenching amounts of the fluorescent dye R18, to monitor fusion, and adsorbed onto control BHK cells for 1h at 4°C. Cells were then incubated for 45min at 37°C, and analyzed by immunofluorescence. No fluorescence signal could be detected after liposome binding to the cell surface on ice (Fig 2C) . Similarly, no signal was detected when cells were allowed to internalize liposomes for less than 30-45 min at 37°C (Fig 2C and not shown) , demonstrating that dye exchange did not occur to any significant extent under our conditions. At later time-points, R18 fluorescent punctae, revealing liposome fusion, appeared intracellularly. These showed a typical late endosome-like pattern and colocalized with both Lamp1 (Fig 2C) , a major glycoprotein of late endosomes and lysosomes (39) , and with LBPA itself (Fig S4D) . The Gprotein showed a similar distribution and colocalized with the late endocytic marker CD63-GFP (24) (Fig S4E) . Using the liposomes, LBPA delivery was successful, since LBPA labeling was more intense and colocalized with Lamp1 (not show) in typical late endosomal-like structures (Fig S4D) , and since the total LBPA content of liposome-treated cells increased ≈2 fold (Fig 2D) , from ≈1% in control cells (5) to ≈2% of total phospholipids. This increase agrees well with our estimate of the amounts of liposomes taken up by cells after G-protein quantification (not shown).
LBPA recomplementation after Alix depletion. Alix knockdown causes a concomitant reduction in both LBPA levels (Fig 1 A-C) and lumenal membranes of late endosomes (Fig 1E) . We thus used liposomes to recomplement Alix siRNA-treated cells with exogenous LBPA. As in Fig 1D-E , late endosomes were labeled with endocytosed HRP pulsed for 15min and chased for 30min at 37°C. After processing cells for HRP cytochemistry and electron microscopy, micrographs were taken at random and analyzed in a blind fashion. Strikingly, HRP-labeled structures of cells re-complemented with 2,2'-dioleoylLBPA, the main LBPA isoform in BHK cells, exhibited the characteristic multivesicular appearance of late endosomes in BHK cells (Fig  3A) , which could not be distinguished from the appearance of late endosomes in controls (see Fig 1D) . These effects were specific, since recomplementation with the 3,3'-dioleoylLBPA isoform did not restore lumenal membranes in late endosomes (Fig 3B) , which then resembled the empty endosomes observed in Alix knockdown cells (Fig 1E) . The appearance of late endosomes in 3,3'-LBPA-treated cells is unlikely to result from some undesired effect of this isoform, since cells containing late endosomes with a normal WT morphology were occasionally seen in the same preparations (inset Fig 3B) , presumably corresponding to untransfected cells. These observations fit nicely with our previous data that 2,2'-dioleoylLBPA, but not the 3,3'-isoform, can interact with Alix and exhibit the inherent capacity to form multivesicular liposomes in vitro (13) .
Since addition of exogenous 2,2'-dioleoylLBPA could restore lumenal membranes in late endosomes of cells treated with Alix siRNAs, we wondered whether the same treatment might overcome the cholesterol deficiency observed after Alix knockdown ( Fig  1A-B) . We could not quantify cholesterol directly in these siRNA-and liposome-treated cells, because amounts were limiting. However, an analysis by light microscopy showed that addition of exogenous 2,2'-dioleoylLBPA restored the cholesterol distribution observed after filipin staining, much like LBPA itself ( Fig  3C; quantification in 3D) . Cholesterol staining showed the characteristic pattern observed in controls, presumably corresponding to the plasma membrane, endosomes and TGN (8, 29) . These depletion-recomplementation experiments indicate that LBPA plays a direct role in the maintenance of endosomal cholesterol levels. Under physiological conditions, cholesterol accumulates in intralumenal membranes (3, 4) , suggesting that free cholesterol -e.g. released after LDL endocytosis and de-esterification -is captured by LBPA-rich internal membranes, presumably because these are more abundant than the limiting membrane (5). In siRNAtreated cells, when LBPA levels are decreased and lumenal membranes reduced (Fig 1) , cholesterol may not be efficiently retained in endosomes, leading to increased leakage (see model Fig 5) . By restoring lumenal membranes (Fig 3B) , the addition of exogenous LBPA presumably also restores the endosomal capacity to store cholesterol (Fig 3C-D) . We thus conclude that LBPA itself plays a direct role in the maintenance of endosomal cholesterol, perhaps because LBPA-rich membranes help buffer membrane cholesterol (Fig 5) .
Niemann-Pick type C cholesterol storage disorder. The existence of a link between cholesterol storage and LBPA-membranes is further supported by observations that LBPA and cholesterol shift in parallel under diverse cellular conditions. Cholesterol decreases when LBPA decreases after Alix knockdown, and is restored upon LBPA re-loading. Consistently, both are also decreased upon sterol carrier protein-2 expression (6). Conversely, LBPA accumulates when cholesterol accumulates in vitro (Fig 2B) and in NPC cells in vivo (12) . It may be that cholesterol accumulation and LBPA are not linked functionally in NPC cells. There is, however, a distinct possibility that LBPA and other lipids accumulate in diseased cells as a compensatory mechanism to accommodate excess cholesterol. Obviously, if this is the case, this mechanism does not suffice to overcome the lipidosis -Alix is unlikely to be limiting, since its expression does not change in NPC or U18666A-treated cells (not shown). One might thus speculate that LBPA increases in diseased cells to compensate for cholesterol accumulation, until LBPA production and the endosomal system collapse under cholesterol overload (40, 41) . LBPA itself may eventually become limiting in NPC cells (see model Fig 5) . To test this hypothesis, we treated well-established 93.41 human NPC skin fibroblasts (42, 43) , with LBPA-containing liposomes.
After treatment with proteoliposomes containing LBPA for 8h at 37°C, as above ( Fig  2C and 3C) , LBPA was increased ≈ 1.6 fold ( Fig  4C) -a range similar to that observed in BHK cells ( Fig  2D) . Strikingly, cholesterol accumulation was significantly reduced in most liposome-treated NPC cells (Fig. 4A) , which then showed an intracellular pattern reminiscent of healthy cells (see Fig 1A and 3C) , including fibroblasts (7). To quantify these effects, NPC cells were divided into three categories, because of their heterogeneous phenotype: I) strong accumulation of cholesterol, which sometimes occupied most of the cytoplasm volume, II) reduced (intermediate) and III) low accumulation (Fig 4B and D) . [Some differences in the percentages of cells in each category in Fig 4B and D reflect variations in separate series of experiments presumably due to culture conditions.] LBPA-containing liposomes reduced the number of cells with a strong phenotype ≈2-3 fold, with a concomitant increase in cells with intermediate and mild phenotypes (Fig 4B and  D) . These effects were specific, since liposomes lacking LBPA were essentially without effects, while liposomes that contained 20Mol% cholesterol (DOPC:DOPE:Chol 60:20:20), instead of 20Mol% LBPA, further increased cholesterol levels (Fig 4B) .
LBPA isoforms and analogues. The observed effects were also specific for the 2,2'-dioleoyl LBPA isoform, since cholesterol accumulation was not significantly affected by liposomes containing 3,3'-dioleoyl LBPA, or a triple acylated version of the lipid (semi-LBPA) (Fig 2A) , which was reported to be present in vaccinia virus and perhaps in the Golgi apparatus (44) (Fig 4B) . Hence, esterification of the acyl chains to the 2 and 2' positions of the glycerol backbone is essential for LBPA function in cholesterol clearance. It is attractive to believe that LBPA functions in cholesterol clearance and endosomal membrane dynamics are linked since 2,2'-LBPA but not 3-3' LBPA i) interacts with Alix, ii) supports the invagination of artificial membranes in vitro (13) and iii) restores lumenal membranes in Alix knockdown cells (Fig 3A) .
Since acyl chain addition to the 2 and 2' positions is essential for LBPA functions, we then investigated whether the 2 and 2' linking groups were also important. Liposomes containing either enantiomeric (R,R or S,S) form of the bisether analogue of R,R 2,2'-dioleoyl-LBPA (20) (Fig S1B) did not show any significant effect, when compared to the natural bisester lipid (Fig 4D) . This further establishes the specificity of 2,2'-LBPA action in cholesterol clearance, and demonstrates that acylation to the glycerol backbone via a carbonyl group is required for function. Altogether, these data show that cholesterol clearance from NPC endosomes is facilitated by the addition of exogenous LBPA, indicating that LBPA itself becomes limiting in the disease, presumably because cholesterol has accumulated beyond the capacity of endosomal membranes. Similarly, M87 mutant CHO cells harbor a mutation in a gene distinct from NPC1 or NPC2 but show NPC-like cholesterol accumulation in late endocytic compartments, perhaps because excessive internalization of LDL cholesterol exceeds the capacity of NPC1-containing late endosomes and leads to cholesterol accumulation (31) . Then, this pathological accumulation causes a complete traffic jam that collapses the endosomal system (40, 41) , and eventually interferes with cholesterol-dependent functions of endosomes (28) , including early-to-late endosome transport (45) and late endosome motility (46, 47) . It is attractive to speculate that LBPA may play a similar role in other lipidosis that are accompanied by cholesterol accumulation in endosomes and lysosomes (48, 49 ). In conclusion, our observations indicate that the precise modulation of a specific, natural lipid species in a targeted organelle can lead to the partial reversion of a disease phenotype. The identification of LBPA metabolic enzymes may thus provide new biomedical strategies to overcome some of the problems and defects associated with these storage diseases.
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Puri, V., Watanabe, R., Dominguez, M., Sun, X., Wheatley, C. Fig. 1 . Alix and LBPA. (A) BHK cells were treated with siRNAs against Alix (siRNA Alix) or mocktreated (control, ctrl) for 72h. Alix siRNAs were identical to those used in human cells (13) , since their target region is identical in hamster (see Fig S1A) . Cells were then stained with filipin to reveal cholesterol, and with antibodies against LBPA, and analyzed by double-channel fluorescence microscopy. LBPA and cholesterol are decreased after Alix knockdown (but both exhibit their characteristic punctate pattern at longer exposure times -not shown). . Then, cells were incubated with HRP to label the late endosome content, and processed for electron microscopy, as in Fig 1D-E. Bar, 1µm. (C-D) Cells were treated with Alix siRNA or mocktreated, and then with liposomes containing 2,2'-dioleoylLBPA (siRNA + LBPA), as in B, and processed for fluorescence microscopy after staining with anti-LBPA antibodies and filipin to reveal cholesterol (C). Filipin staining was significantly reduced after Alix knockdown (middle panels), when compared to the mock-treated controls (upper panels), and could be restored after recomplementation with 2,2'-dioleoylLBPA (lower panels). Cells with a reduced or a normal filipin staining pattern were then counted and are expressed (D) as a percentage of the total number of cells in each experiment (≈200 cells from three independent experiments). This releases free cholesterol that, because of its low partition coefficient, is likely to become efficiently incorporated into the closest membranes. These are likely to be predominantly intralumenal membranes, since these are abundant within multivesicular endosomes. Consistently, cholesterol was found to be abundant within intralumenal membranes (3, 4) . Cholesterol must be redistributed to the endosome limiting membrane so that it becomes available for export to other cellular destinations, and this redistribution is likely to involve the back-fusion of intralumenal vesicles (16, 17) . (B) Alix knockdown causes a concomitant reduction in the late endosomal phospholipid LBPA (13) . In good agreement with the fact that LBPA is abundant in intralumenal vesicles (5), the late endosomes of Alix knockdown cells are depleted of intralumenal vesicles. Cholesterol clearance seems to be accelerated, presumably because the cholesterol buffering capacity of endosomal membranes is decreased when LBPA and lumenal vesicles are reduced. This notion is further supported by observations that the addition of exogenous LBPA restores both cholesterol levels and intralumenal membranes within late endosomes. (C) LBPA and other lipids accumulate in Nieman-Pick C (NPC) cells, concomitantly with an increase in the size of the late endosomal compartment (51), presumably as a compensatory mechanism to accommodate excess cholesterol. Obviously, this mechanism does not suffice to overcome the lipidosis, and eventually cholesterol accumulates beyond the capacity of endosomal membranes, leading to a traffic jam that collapses the endosomal system (40, 41) . Consistently, we find that the addition of exogenous LBPA to NPC cells reduces the pathological accumulation of cholesterol, presumably because LBPA became limiting in NPC cells due to cholesterol overload. 
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